TY - JOUR
T1 - Ability of epidemiological studies to monitor HPV post-vaccination dynamics
T2 - a simulation study
AU - Bonneault, M. lanie
AU - Delarocque-Astagneau, Elisabeth
AU - Flauder, Maxime
AU - Bogaards, Johannes A.
AU - Guillemot, Didier
AU - Opatowski, Lulla
AU - Thiébaut, Anne C. M.
N1 - Funding Information: MB was funded by the INCa [grant DOC 2017-123] and MGEN, and her work was supported Funding Information: M. B. was funded by the INCa [grant DOC 2017-123] and MGEN, and her work was supported by internal resources of Institut Pasteur, the French National Institute of Health and Medical Research (Inserm) and the University of Versailles Saint-Quentin-en-Yvelines (UVSQ). Publisher Copyright: Copyright © The Author(s), 2023. Published by Cambridge University Press.
PY - 2023/2/2
Y1 - 2023/2/2
N2 - Genital human papillomavirus (HPV) infections are caused by a broad diversity of genotypes. As available vaccines target a subgroup of these genotypes, monitoring transmission dynamics of nonvaccine genotypes is essential. After reviewing the epidemiological literature on study designs aiming to monitor those dynamics, we evaluated their abilities to detect HPV-prevalence changes following vaccine introduction. We developed an agent-based model to simulate HPV transmission in a heterosexual population under various scenarios of vaccine coverage and genotypic interaction, and reproduced two study designs: post-vs-prevaccine and vaccinated-vs-unvaccinated comparisons. We calculated the total sample size required to detect statistically significant prevalence differences at the 5% significance level and 80% power. Although a decrease in vaccine-genotype prevalence was detectable as early as 1 year after vaccine introduction, simulations indicated that the indirect impact on nonvaccine-genotype prevalence (a decrease under synergistic interaction or an increase under competitive interaction) would only be measurable after >10 years whatever the vaccine coverage. Sample sizes required for nonvaccine genotypes were >5 times greater than for vaccine genotypes and tended to be smaller in the post-vs-prevaccine than in the vaccinated-vs-unvaccinated design. These results highlight that previously published epidemiological studies were not powerful enough to efficiently detect changes in nonvaccine-genotype prevalence.
AB - Genital human papillomavirus (HPV) infections are caused by a broad diversity of genotypes. As available vaccines target a subgroup of these genotypes, monitoring transmission dynamics of nonvaccine genotypes is essential. After reviewing the epidemiological literature on study designs aiming to monitor those dynamics, we evaluated their abilities to detect HPV-prevalence changes following vaccine introduction. We developed an agent-based model to simulate HPV transmission in a heterosexual population under various scenarios of vaccine coverage and genotypic interaction, and reproduced two study designs: post-vs-prevaccine and vaccinated-vs-unvaccinated comparisons. We calculated the total sample size required to detect statistically significant prevalence differences at the 5% significance level and 80% power. Although a decrease in vaccine-genotype prevalence was detectable as early as 1 year after vaccine introduction, simulations indicated that the indirect impact on nonvaccine-genotype prevalence (a decrease under synergistic interaction or an increase under competitive interaction) would only be measurable after >10 years whatever the vaccine coverage. Sample sizes required for nonvaccine genotypes were >5 times greater than for vaccine genotypes and tended to be smaller in the post-vs-prevaccine than in the vaccinated-vs-unvaccinated design. These results highlight that previously published epidemiological studies were not powerful enough to efficiently detect changes in nonvaccine-genotype prevalence.
KW - Agent-based modelling
KW - genotype interactions
KW - human papillomavirus
KW - observational study simulations
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=85147693960&partnerID=8YFLogxK
U2 - https://doi.org/10.1017/S0950268823000122
DO - https://doi.org/10.1017/S0950268823000122
M3 - Article
C2 - 36727199
SN - 0950-2688
VL - 151
JO - Epidemiology and Infection
JF - Epidemiology and Infection
M1 - e31
ER -